论文部分内容阅读
作平阳霉素(BLMA_5)对人食管鳞状细胞癌裸小鼠移植瘤(Eca910709)进行治疗,按15mg/kg体重腹腔注射给药,经重复实验,结果抑瘤率为58%~70%(P<0.01),说明BLMA_5对Eca910709有明显的抑瘤作用。经三个疗程治疗,Eca910709即对BLMA_5产生耐药,表现在抑瘤率从70%(P<0.01)递减为34%(P<0.05)和6%(P>0.05)。给药剂量增加至30mg/kg,BLMA_5对己耐药的Eca910709再次显示一定的抑瘤作用(抑瘤率为44%,P<0.01)。本实验结果对临束治疗食管癌将有较大应用价值。
For Pingyangmycin (BLMA_5) treatment of human esophageal squamous cell carcinoma nude mouse transplant tumor (Eca910709), according to 15mg/kg body weight intraperitoneal injection, after repeated experiments, the results of tumor inhibition rate of 58% to 70% ( P<0.01), indicating that BLMA_5 has significant anti-tumor effect on Eca910709. After three courses of treatment, Eca910709 was resistant to BLMA5, showing a decrease in tumor inhibition rate from 70% (P<0.01) to 34% (P<0.05) and 6% (P>0.05). The dose increased to 30 mg/kg, and the anti-tumor drug Eca910709 of BLMA_5 showed a certain inhibitory effect (inhibitory rate was 44%, P<0.01). The results of this experiment will have great value in the treatment of esophageal cancer.